EUCTR2018-001930-17-HU进行中（未招募）1 期
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS WITH MODERATE-TO-SEVERE PRURITUS, WITH A 52-WEEK OPEN-LABEL EXTENSION - CR845-CLIN3103
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria:
- •To be eligible for inclusion into the Double-blind Phase of the study, a
- •patient must meet the following criteria:
- •1. Willing and able to provide written informed consent prior to
- •participating in this study;
- •2. Able to communicate clearly with the Investigator and staff,
- •able to understand the study procedures, and able and willing
- •to comply with the study requirements; 3. Male or female 18 years of age or older;
- •4. Has end-stage renal disease (ESRD) and has been on
- •hemodialysis 3 times per week for at least 3 months prior to
- •the start of screening;
- •Note 1: Patients who require an occasional additional dialysis
- •treatment to manage fluid overload or electrolyte excesses
- •may be enrolled as long as it is anticipated that no more than
- •1 such treatment will be required in any given week and no
- •more than 4 occasions during the 12-week double-blind
- •period. Patients routinely on 4 dialyses a week will not be
- •Note 2: Patients receiving in-home hemodialysis may
- •participate as long as they have switched to in-center
- •hemodialysis at least 2 weeks prior to screening and plan to
- •remain on in-center hemodialysis for the duration of the
- •5. If female, is not pregnant or nursing during any period of the
- •6. If female:
- •a. Is surgically sterile; or
- •b. Has been amenorrhoeic for at least 1 year and is over the
- •age of 55 years; or
- •c. Has a negative serum pregnancy test at screening and
- •agrees to use acceptable contraceptive measures
- •(eg, hormonal contraceptives, barrier with spermicide,
- •intrauterine device, vasectomized partner, or abstinence)
- •from the time of informed consent until 7 days after the
- •last dose of study drug;
- •7. If male, agrees not to donate sperm after the first dose of study
- •drug until 7 days after the last dose of study drug, and agrees to
- •use a condom with spermicide or abstain from heterosexual
- •intercourse during the study until 7 days after the last dose of
- •study drug. (Note: No restrictions are required for a
- •vasectomized male provided his vasectomy was performed
- •=4 months prior to screening);
- •8. Has a prescription dry body weight between 40.0 and 135.0 kg,
- •9. Has at least 2 single-pool Kt/V measurements =1.2, or at least
- •2 urea reduction ratio measurements =65%, or 1 single-pool
- •Kt/V measurement =1.2 and 1 urea reduction ratio
- •measurement =65% on different dialysis days during the
- •3 months period prior to screening;
- •10. Prior to randomization:
- •a. Has completed at least four out of eight Worst Itching
- •Intensity Numerical Rating Scale (NRS) worksheets fromhe start of the 7-day Run-in Period up to and including the
- •pre-randomization assessment on Day 1;
- •b. Has a mean baseline Worst Itching Intensity NRS score
- 另有 9 项未显示
排除标准
- •Exclusion Criteria:
- •A patient will be excluded from the Double-blind Phase of the study if
- •any of the following criteria are met:
- •1. Known noncompliance with dialysis treatment that in the
- •opinion of the Investigator would impede completion or
- •validity of the study;
- •2. Scheduled to receive a kidney transplant during the study;
- •3. Known history of allergic reaction to opiates, such as hives
- •(Note: side effects related to the use of opioids, such as
- •constipation or nausea, would not exclude patients from the
- •4. Has a concomitant disease or a history of any medical
- •condition that, in the opinion of the Investigator, could pose
- •undue risk to the patient, impede completion of the study
- •procedures, or would compromise the validity of the study
- •measurements, including, but not limited to:
- •a. Known or suspected history of alcohol, narcotic, or other
- •drug abuse, or substance dependence within 12 months
- •prior to screening;
- •b. Significant systolic or diastolic heart failure (eg, New
- •York Heart Association Class IV congestive heart failure
- •[Appendix 1, Section 14.1]);
- •c. Severe mental illness or cognitive impairment (eg,
- •d. Any other relevant acute or chronic medical or
- •neuropsychiatric condition within 3 months prior to
- •screening (eg, diagnosis of encephalopathy, coma,
- •5. New or change of treatment received for itch including
- •antihistamines and corticosteroids (oral, IV, or topical) within
- •14 days prior to screening; 6. New or change of prescription for opioids, gabapentin, or
- •pregabalin within 14 days prior to screening;
- •7. Received another investigational drug within 30 days prior to
- •the start of screening or is planning to participate in another
- •clinical study while enrolled in this study;
- •8. In the opinion of the Investigator, has pruritus attributed to a
- •cause other than ESRD or its complications (eg, patients with
- •concomitant pruritic dermatological disease or cholestatic liver
- •disease) (Note: Patients whose pruritus is attributed to ESRD
- •complications, such as hyperparathyroidism,
- •hyperphosphatemia, anemia, or the dialysis procedure or
- •prescription may be enrolled);
- •9. Has localized itch restricted to the palms of the hands;
- •10. Has pruritus only during the dialysis session (by patient
- •11. Is receiving ongoing ultraviolet B treatment and anticipates
- •receiving such treatment during the study;
- •12. Participated in a previous clinical study with CR845.
研究者
相似试验
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS =1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURESEpilepsy with partial onset seizuresMedDRA version: 21.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-000717-20-Outside-EU/EEACB Biosciences Inc.255
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS =1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURESEUCTR2013-000717-20-BGCB Biosciences Inc.255
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS =1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURESEpilepsy with partial onset seizuresMedDRA version: 20.0Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-000717-20-PLCB Biosciences Inc.244
进行中（未招募）
1 期
A Study of Idasanutlin with Cytarabine versus Cytarabine plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia.Relapsed or refractory acute myeloid leukemia (AML).MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-003065-15-BEF. Hoffmann-La Roche Ltd440
进行中（未招募）
1 期
EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS >=1 MONTH TO <4 YEARS WITH PARTIAL-ONSET SEIZURESEUCTR2013-000717-20-ESCB Biosciences Inc.244